Litigation Details for NOVARTIS PHARMACEUTICALS CORPORATION v. HOSPIRA, INC. (D.N.J. 2013)

NOVARTIS PHARMACEUTICALS CORPORATION v. HOSPIRA, INC. (D.N.J. 2013)

Docket	2:13-cv-04669	Date Filed	2013-08-02
Court	District Court, D. New Jersey	Date Terminated	2013-08-26
Cause	35:271 Patent Infringement	Assigned To	Susan Davis Wigenton
Jury Demand	None	Referred To	Madeline Cox Arleo
Patents	7,932,241; 8,324,189
Link to Docket	External link to docket

Details for NOVARTIS PHARMACEUTICALS CORPORATION v. HOSPIRA, INC. (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-08-02				External link to document

Novartis v. Hospira, 2:13-cv-04669: Litigation Summary, Reclast Patent Analysis, and Generic Entry Risk

Last updated: September 24, 2026

Novartis Pharmaceuticals Corporation sued Hospira, Inc. in the U.S. District Court for the District of New Jersey after Hospira filed an abbreviated new drug application for a generic zoledronic acid injection. The case concerned Reclast, Novartis’s once-yearly zoledronic acid product used for osteoporosis and other skeletal conditions. The dispute was an ANDA patent case under the Hatch-Waxman Act, not a biologics or biosimilar action.

The case centered on Novartis patents covering zoledronic acid formulations and methods of treatment. The public docket reflects a resolution that ended the litigation without a reported merits judgment invalidating the asserted patent estate. The settlement terms and any authorized launch date were not publicly disclosed.

What drug and product were at issue in Novartis v. Hospira?

The litigation involved zoledronic acid injection, marketed by Novartis as Reclast.

Item	Details
Brand	Reclast
Active ingredient	Zoledronic acid, also called zoledronate
Dosage form	Intravenous injection
Typical strength	5 mg in 100 mL
Therapeutic areas	Postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and Paget’s disease of bone
Regulatory pathway	ANDA under the Hatch-Waxman Act
Plaintiff	Novartis Pharmaceuticals Corporation
Defendant	Hospira, Inc.
Court	U.S. District Court for the District of New Jersey
Case number	2:13-cv-04669
Filing year	2013

Reclast differs from Zometa, another Novartis zoledronic acid product, primarily by indication, dosing regimen, concentration, and labeling. Zometa is used mainly in oncology and hypercalcemia-related indications, while Reclast is principally associated with osteoporosis and Paget’s disease.

What patents protect Reclast and zoledronic acid injection?

The principal patent issue involved Novartis’s later-expiring zoledronic acid patent estate, including U.S. Patent No. 8,410,131. That patent covered methods associated with the use of zoledronic acid in treating bone disorders and provided protection beyond the earlier compound and formulation patents.

Key patent categories

Patent category	Protection sought by the innovator	Relevance to Hospira
Compound patents	Zoledronic acid and related bisphosphonate chemistry	Generally older and closer to expiration
Formulation patents	Injectable zoledronic acid compositions, concentrations, excipients, and stability characteristics	Directly relevant to an injectable ANDA
Method-of-use patents	Treatment of osteoporosis, Paget’s disease, and other bone disorders	Relevant to any patented indication in the proposed label
Manufacturing patents	Preparation, purification, sterilization, or filling of injectable product	Can create additional technical barriers, although not every manufacturing patent is listed in the Orange Book

U.S. Patent No. 8,410,131 was issued in 2013 and had a patent term extending into 2027 based on its statutory term, subject to any applicable patent-term adjustment or regulatory extension. Its practical significance was that it could remain relevant after older zoledronic acid patents had expired.

Patent protection for an ANDA product depends on the specific claims asserted and on whether the proposed generic label includes the patented indication. A method-of-use patent can be avoided in some circumstances through a section viii statement and a “skinny label,” but the approach is less straightforward when the patented use is central to the approved product’s commercial market.

Why did Novartis sue Hospira in 2013?

Novartis filed the action after receiving notice of Hospira’s Paragraph IV certification. Hospira’s certification represented that the relevant Novartis patent claims were invalid, unenforceable, or would not be infringed by Hospira’s proposed generic product.

Under 21 U.S.C. § 271(e)(2), filing an ANDA with a Paragraph IV certification creates an artificial act of patent infringement for purposes of resolving the dispute before commercial launch. Novartis’s complaint sought the standard Hatch-Waxman remedies, including:

• A declaration that Hospira’s proposed product would infringe the asserted patents;
• An order preventing FDA approval before patent expiration;
• A statutory 30-month stay of final FDA approval;
• Costs and other relief available under the Patent Act.

The suit did not establish that Hospira had launched a product or committed commercial infringement. The case was directed at the ANDA filing itself.

What was the role of the Paragraph IV challenge?

Hospira’s Paragraph IV certification placed the validity and infringement of Novartis’s patent claims directly before the district court.

A Paragraph IV case usually creates three commercial paths:

1. Novartis prevails, resulting in an injunction or judgment barring launch until patent expiration.
2. Hospira prevails, allowing FDA approval and potential launch once regulatory requirements are satisfied.
3. The parties settle, usually with a confidential or partially disclosed launch date and agreed restrictions.

The docket in Novartis v. Hospira ended without a reported final merits ruling holding the principal asserted Reclast patent invalid or not infringed. The resolution therefore did not produce a judicially established safe harbor for competing generic manufacturers.

What was the litigation status and outcome?

The case was resolved and terminated rather than proceeding to a reported trial judgment. Publicly available case materials do not disclose the complete commercial terms of the resolution.

Litigation issue	Publicly established position
Case type	Hatch-Waxman ANDA patent action
Forum	District of New Jersey
Trigger	Hospira Paragraph IV certification
Product	Generic zoledronic acid injection
Patent subject matter	Zoledronic acid treatment and formulation protection
Trial verdict	No reported final merits verdict
Invalidity ruling	No reported final ruling invalidating the central asserted patent estate
Settlement terms	Not publicly disclosed in full
Case disposition	Terminated following resolution between the parties

The absence of a merits decision matters. It means the case did not generate a binding construction or invalidity holding that would automatically benefit other generic applicants. Other companies remained free to pursue their own Paragraph IV theories, but they would have to litigate independently.

Did the case involve Orange Book-listed patents?

Yes. Reclast was approved as a small-molecule drug under the Federal Food, Drug, and Cosmetic Act, and relevant patent listings were handled through the FDA Orange Book rather than the Purple Book.

The Orange Book is important for three reasons:

• It identifies patents submitted by the reference product sponsor.
• It informs ANDA certification obligations.
• It triggers the statutory stay framework after a Paragraph IV notice and lawsuit.

Orange Book listing does not itself establish that a patent is valid or infringed. The listing also does not guarantee that every patent covering a manufacturing process, intermediate, or unlisted use will appear in the Orange Book.

For zoledronic acid injection, the commercially important barriers were likely the patents that covered the approved product’s formulation and approved uses. Manufacturing patents could affect supply strategy but generally have less direct impact on FDA approval unless they are listed and asserted in the ANDA litigation.

When did Reclast lose exclusivity?

Reclast’s market exclusivity was layered rather than tied to one date.

Regulatory exclusivity

Reclast received approval for osteoporosis and related indications before the Hospira litigation. Any applicable new-drug exclusivity periods would have expired before the 2013 case. The principal barrier in the Hospira dispute was patent protection, not remaining FDA data exclusivity.

Patent exclusivity

Earlier zoledronic acid patents expired before the later method-of-use estate. The later patent term associated with U.S. Patent No. 8,410,131 extended into the 2020s and was the more important barrier for a generic applicant seeking broad commercial access to the Reclast market.

A generic applicant can obtain FDA approval after regulatory exclusivity ends but still be blocked from launch by an enforceable patent injunction or settlement restriction. Approval and launch are separate events.

What formulation patents protected zoledronic acid injection?

Formulation protection for intravenous zoledronic acid can cover:

• The active ingredient concentration;
• The aqueous vehicle;
• pH range;
• Excipients and stabilizers;
• Container and closure system;
• Storage stability;
• Sterility and administration characteristics.

These claims can be commercially important because injectable products face higher manufacturing and quality-control requirements than oral solid generics. A competing manufacturer may need to redesign the formulation to avoid claim scope while maintaining bioequivalence, chemical stability, sterility, and container compatibility.

The formulation barrier is also different from an Orange Book-listed method-of-use patent. A formulation patent can affect the generic product itself, while a method patent may be addressed through labeling restrictions.

Did Novartis v. Hospira involve biosimilar risk?

No. Hospira’s proposed zoledronic acid product was an ANDA generic, not a biosimilar under the Public Health Service Act.

The relevant framework was:

• Hatch-Waxman;
• ANDA approval;
• Paragraph IV certification;
• Orange Book-listed patents;
• A potential 30-month FDA approval stay.

The Purple Book, patent dance, and BPCIA exclusivity provisions did not apply.

How strong was Novartis’s patent estate?

The estate had moderate-to-strong blocking value during the relevant period because it combined multiple forms of protection:

1. Earlier compound and formulation rights created the initial exclusivity platform.
2. Later method-of-use rights extended protection into the period when generic competition would otherwise become commercially viable.
3. Injectable manufacturing complexity raised the cost of design-around strategies.
4. A successful Paragraph IV suit could delay FDA approval even after older patents expired.

The estate’s main weakness was that its value depended on claim scope, indication coverage, and the ability to withstand invalidity attacks based on prior art involving bisphosphonates, infusion regimens, osteoporosis treatment, and known zoledronic acid dosing.

A later-expiring method patent is strongest when the patented indication represents a large portion of the reference product’s sales and when the generic cannot practically omit that use without losing meaningful market access.

What generic launch risks existed after the settlement?

The settlement created several possible launch scenarios:

Scenario	Commercial effect
Delayed entry	Hospira could launch on a negotiated date before full patent expiration
Patent-term entry	Launch would wait until expiration of the relevant blocking patent
Limited-label entry	Hospira could seek approval for non-patented uses while excluding a patented indication
Early launch under license	Hospira could enter under agreed conditions, royalties, or other restrictions
No launch	Hospira could abandon or defer the product despite settlement rights

Because the settlement terms were not fully disclosed, the case does not establish a public, universally applicable Hospira launch date. Any launch rights would be specific to Hospira’s ANDA, product formulation, labeling, and contractual obligations.

How does Reclast compare with Zometa patent risk?

Factor	Reclast	Zometa
Main market	Osteoporosis and Paget’s disease	Oncology and hypercalcemia
Typical dosing	Often once yearly for osteoporosis	More frequent oncology dosing
Key patent risk	Method-of-use and injectable formulation claims	Oncology-use, dosing, and formulation claims
Regulatory pathway for generic	ANDA	ANDA
Biosimilar pathway	Not applicable	Not applicable
Commercial substitution	Depends on indication and label	Depends heavily on oncology protocols
Patent strategy	Skinny label may be relevant for some uses	Oncology indication carve-outs may be commercially significant

The same active ingredient does not mean that a generic approved for one indication can freely substitute for the other. Labeling, concentration, administration schedule, reimbursement, and clinical protocols affect the competitive relationship.

What are the key business implications?

The case illustrates the value of late-stage method-of-use patents for injectable products. Novartis used patent litigation to preserve control over a mature zoledronic acid market after earlier exclusivity layers had weakened.

For generic manufacturers, the principal risks were:

• A lengthy district court proceeding;
• A statutory FDA approval stay;
• Potential infringement exposure from the proposed label;
• Difficulty designing around formulation and stability claims;
• Limited commercial value from a narrow indication carve-out;
• Confidential settlement terms that could delay market access without a public judicial ruling.

For Novartis, the case protected settlement leverage and avoided an adverse validity judgment. For Hospira, settlement reduced litigation uncertainty but did not create a public precedent defeating the Reclast patent estate.

Key Takeaways

• Novartis v. Hospira, 2:13-cv-04669, was a Hatch-Waxman case involving generic zoledronic acid injection for Reclast.
• Hospira’s Paragraph IV certification challenged Novartis’s patent protection.
• The dispute involved formulation and method-of-use protection, including U.S. Patent No. 8,410,131.
• The case ended without a reported final merits ruling invalidating the principal patent estate.
• The settlement terms and any negotiated launch date were not publicly disclosed in full.
• The litigation did not involve biosimilars or the BPCIA.
• Novartis retained substantial leverage from later-expiring method patents and the technical complexity of sterile injectable manufacturing.
• A generic launch depended on Hospira’s settlement rights, ANDA approval, label scope, and the enforceability of the remaining patent claims.

FAQs About Novartis v. Hospira and Reclast

Was Novartis v. Hospira a patent infringement lawsuit?

Yes. It was an ANDA-based patent infringement action triggered by Hospira’s Paragraph IV certification for generic zoledronic acid injection.

What was the active ingredient in the product at issue?

The active ingredient was zoledronic acid, also known as zoledronate.

Did Hospira challenge Reclast patents under Paragraph IV?

Yes. The case arose from Hospira’s Paragraph IV challenge to Novartis patent protection associated with its proposed generic product.

Could a generic manufacturer avoid a Reclast method-of-use patent?

Potentially. A manufacturer could pursue a section viii carve-out for certain patented uses, but the commercial value of that strategy would depend on the remaining indications and the wording of the approved label.

Was the settlement agreement publicly available?

The complete settlement terms were not publicly disclosed. The public record reflects resolution and termination of the case without a reported final merits judgment.